Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim Â

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 7, 2012, Pages 997-1007

  Willmann, Stefan ^a   Thelen, Kirstin ^a   Lippert, Jörg ^a  

^a BAYER AG   (Germany)

Author keywords

dissolution; food effect; interspecies scaling; pharmacokinetics; physiologically based pharmacokinetics

Indexed keywords

CILOSTAZOL;

ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; IN VIVO STUDY; NONHUMAN; SIMULATION;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DIET; DOGS; DOSAGE FORMS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOFTWARE; SOLUBILITY;

EID: 84862159118     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01534.x     Document Type: Article

References (40)

1. Shimada J, et al,. Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs. Targets 2002; 1: 196-205. (Pubitemid 40432671)
2. Swaan PW, Ekins S,. Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today 2005; 10: 1191-1200. (Pubitemid 41327776)
3. Delaney J,. Modelling iterative compound optimisation using a self-avoiding walk. Drug Discov Today 2009; 14: 198-207.
4. Leahy DE,. Progress in simulation modelling for pharmacokinetics. Curr Top Med Chem 2003; 3: 1257-1268.
5. De Buck SS, Mackie CE,. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 2007; 3: 865-878. (Pubitemid 350285340)
6. Nestorov I,. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007; 3: 235-249. (Pubitemid 47321518)
7. Edginton AN, et al,. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 1143-1152.
8. Rowland M, et al,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
9. Zhao P, et al,. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259-267.
10. Eissing T, et al,. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2011; 2: 4.
11. Willmann S, et al,. PK-Sim: a physiologically based pharmacokinetic 'whole-body' model. Biosilico 2003; 1: 121-124. (Pubitemid 40416764)
12. Willmann S, et al,. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34: 401-431. (Pubitemid 46873033)
13. Dressman JB, et al,. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 2008; 47: 655-667.
14. Costa P, Sousa Lobo JM,. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13: 123-133. (Pubitemid 32288781)
15. Thelen K, et al,. Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. J Pharm Sci 2010; 99: 2899-2904.
16. Johnson KC,. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev Ind Pharm 2003; 29: 833-842. (Pubitemid 37203685)
17. Willmann S, et al,. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 2010; 76: 83-94.
18. Willmann S, et al,. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 2003; 20: 1766-1771. (Pubitemid 37449449)
19. Willmann S, et al,. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47: 4022-4031. (Pubitemid 38970963)
20. Plusquellec Y, et al,. A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption. Med Eng Phys 1999; 21: 525-532.
21. Yu LX, Amidon GL,. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119-125. (Pubitemid 29459038)
22. Agoram B, et al,. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl. 1): S41-S67. (Pubitemid 32905355)
23. Jamei M, et al,. A novel physiologically-based mechanistic model for predicting oral drug absorption: the advanced dissolution, absorption, and metabolism (ADAM) model. PKUK. Edinburgh, UK., 2007.
24. Jamei M, et al,. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225-237.
25. Thelen K, et al,. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans-part I: oral solutions. J Pharm Sci 2011; 100: 5324-5345.
26. Thelen K, et al,. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans-part II: extension to describe performance of solid dosage forms. J Pharm Sci 2012; 101: 1267-1280.
27. Amidon GL, et al,. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
28. CDER/FDA (U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research). Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on A Biopharmaceutics Classification System. Rockville, MD: CDER/FDA (U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research), 2000.
29. Dressman JB, Reppas C, eds. Oral Drug Absorption: Prediction and Assessment, Drugs and the Pharmaceutical Sciences, 2nd edn. New York: Informa Healthcare, 2010.
30. Sheng JJ, Amidon GL,. The biopharmaceutics classification system: recent applications in pharmaceutical discovery, development, and regulation. In:, Dressman JB, Reppas C, eds. Oral Drug Absorption: Prediction and Assessment. New York: Informa Healthcare, 2010: 138-154.
31. Bayer Technology Services GmbH. User Manual PK-Sim 4.2. Leverkusen, Germany: Bayer Technology Services GmbH, 2009.
32. Jinno J, et al,. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006; 111: 56-64. (Pubitemid 43289995)
33. Kostewicz ES, et al,. Comparison of dog and human intestinal fluid and its impact on solubility estimations. Eur J Pharm Sci 2002; 17S: S87-S138.
34. Kalantzi L, et al,. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006; 23: 1373-1381. (Pubitemid 43946159)
35. CDER/FDA (U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research). Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, MD: CDER/FDA (U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research), 2002.
36. Willmann S, et al,. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J Pharm Pharmacol 2009; 61: 891-899.
37. Dressman JB, et al,. An update on computational oral absorption simulation. Expert Opin Drug Metab Toxicol 2011; 7: 1345-1364.
38. Effros RM,. Anatomy, development, and physiology of the lungs. GI Motility online. nature publishing group, 2006.
39. Iyer SS, et al,. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm Drug Dispos 2006; 27: 157-170. (Pubitemid 43797112)
40. Marques MRC, et al,. Simulated biological fluids with possible application in dissolution testing. Dissolut Technol 2011; 2011: 15-28.